73 m2) and who wish to fall pregnant be advised that they can provided their blood pressure is well controlled (2C). Note: The degrees of increased risk of each outcome in pregnant women with CKD are difficult to precisely quantify, although have generally been reported in each study to be at least 2-fold higher than in pregnant women without CKD. d. We recommend that patients with CKD planning to fall pregnant should have their medications reviewed and modified prior to conception. The check details anticipated benefits of

each medication should be weighed against its potential risks. In particular, angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) should be discontinued (1D). Chronic kidney disease is a significant contributor to morbidity and mortality, and represents a major expense to the healthcare system. Early intervention this website with appropriate medical therapies is essential to address this public health burden and may reduce the progression of CKD and cardiovascular risk by up to 50%.[9] Important risk factors for CKD include diabetes mellitus, hypertension, obesity and smoking. Modification of lifestyle habits (e.g. healthy diet, physical exercise, smoking cessation, moderate alcohol consumption

and weight loss in obese people) may therefore be of value in retarding the progression of CKD. In addition, restriction of dietary protein[31] and augmentation of fluid intake[32] have been recommended as a treatment for retarding CKD progression for over 50 years. While the National Health and Medical Research Council (NHMRC) Dietary Guidelines for Australian Adults (http://www.nhmrc.gov.au/guidelines/publications/n29-n30-n31-n32-n33-n34)

provide useful generalized, evidence-based information about healthy food choices, patients with CKD often require individualized diet prescription by an appropriately qualified dietitian. Diabetes mellitus, particularly type 2, is increasing in prevalence and associated with significant cardiovascular morbidity and mortality. It also represents Resminostat the leading cause of CKD worldwide. Evidence from large, prospective trials indicates that tight glycaemic control in type 1[33] and, to a lesser extent, type 2[34, 35] diabetic patients results in clinically significant preservation of renal function. The optimal level to which glycosylated haemoglobin (HbA1c) should be targeted (<7.0%) is largely based on the Diabetes Control and Complications Trial (DCCT) and UKPDS trials[33-35] but the threshold below which the benefit is lost or at which the incidence of side-effects becomes unacceptable is not clear. Chronic kidney disease is also a well-established independent cardiovascular risk factor. Evidence[36, 37] for anti-platelet therapy suggests that low-dose aspirin reduces the risk of CVD by 25–33%, particularly in patients with established CVD (secondary prevention) or those at high risk (primary prevention).